Teva Pharmaceutical Industries (TEVA) Buildings (2009 - 2025)

Teva Pharmaceutical Industries (TEVA) has reported Buildings for 17 consecutive years, with $2.3 billion the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Buildings rose 18.24% year-over-year to $2.3 billion; the trailing twelve-month figure through Dec 2025 stood at $2.3 billion (up 18.24% YoY), and the FY2025 full-year result was $2.3 billion, up 18.24% from the prior year.
• Buildings climbed to $2.3 billion in Q4 2025 per TEVA's latest filing, from $2.0 billion in the prior quarter.
• Across five years, Buildings topped out at $2.6 billion in Q4 2021 and bottomed at $2.0 billion in Q4 2024.
• Historically, Buildings has averaged $2.4 billion across 5 years, with a median of $2.5 billion in 2022.
• The sharpest annual moves came in 2024 and 2025: Buildings slipped 20.9% in 2024, then increased 18.24% in 2025.
• Over 5 years, Buildings stood at $2.6 billion in 2021, then fell by 4.09% to $2.5 billion in 2022, then gained by 1.02% to $2.5 billion in 2023, then fell by 20.9% to $2.0 billion in 2024, then grew by 18.24% to $2.3 billion in 2025.
• According to Business Quant data, Buildings over the past three periods registered $2.3 billion, $2.0 billion, and $2.5 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.